Retatrutide Side Effects and Open Questions | Doctor Retatrutide
Retatrutide most often caused nausea and bowel trouble
Which retatrutide side effects showed up most? Nausea and bowel trouble led the list. Phase 2 was the middle round that checked results and common problems, while Phase 3 is the larger later round now checking safety in far more people. The problems resemble GLP-1 weight and diabetes shots, which curb hunger. Doctors also watch pulse and thyroid cells. You’ll want to ask which signs need a quick call. I’d note the answer beside your medicine list.
Nausea, diarrhea, vomiting, and constipation were most common
Stomach and bowel symptoms were the most common problems in retatrutide studies. In the Phase 2 weight study, up to 60% of the 12 mg group reported nausea. Diarrhea affected 15–33%, vomiting 21–26%, and constipation 14–18% [1]. Your doctor would need to know which symptom troubles you most.
Most cases were called mild or moderate. Problems were worst while the study amount rose, not after it stayed level [1]. A slow rise was meant to ease them. Most people could continue their assigned amount. A mild group report can’t tell you how hard a symptom might hit you.
A review of several studies found more nausea as the amount rose. Nausea was more common than with placebo [6]. Some people at higher amounts stopped because of gut trouble. Across GLP-1 hunger drugs as a whole, 20–50% stop within the first year. Retatrutide doesn’t yet have that kind of use outside studies. Your reasons could differ.
A few people had serious problems in retatrutide studies
In Phase 2, a small number of people had serious stomach or bowel trouble. Other problems included a faster pulse, gallstones, gallbladder illness, and strong allergic reactions at higher amounts [14]. The words “small number” don’t tell you your own risk.
A 2023 review by Doggrell found much the same safety pattern as GLP-1 weight drugs, which curb hunger. After Phase 1b, the small early testing round, researchers still couldn’t judge the good or bad effects of retatrutide’s third action [18]. Pulse rate was the clearest concern. At higher amounts, the average rose as much as 6.7 beats per minute [14]. Your usual pulse gives your doctor needed context.
That finding helped lead to a Phase 3 safety study [19]. The study checks whether retatrutide changes the risk of major heart trouble. An average pulse rise can’t predict your result.
The studies left out people with certain health risks
Retatrutide is still being tested, so there’s no FDA-approved list of people who can’t take it. The best clue is the list of people kept out of Phase 2. Those rules came from other GLP-1 hunger drugs. The list can’t decide whether retatrutide fits you.
Phase 2 left out people with a personal or family history of a rare thyroid cancer in hormone-making cells. It also left out people with multiple endocrine neoplasia type 2, a rare family illness that can cause tumors in several glands. Those choices came from thyroid tumors in rodents given related GLP-1 drugs [12]. People with past pancreatitis, severe stomach or bowel disease, or an active pregnancy were also left out [1][3]. Your doctor can compare those GLP-1 study rules with your family history.
A study list isn’t an approved drug label. If the FDA approves retatrutide, its label will name who can’t take it and explain the warnings. Until then, the doctor with your records will need to talk through the risks.
The studies watched the gallbladder, pancreas, and kidneys
Some people in Phase 2 had gallstones or a sore, swollen gallbladder. Fast weight loss can raise the chance of gallstones. Related GLP-1 weight drugs, which curb hunger, carry the same concern [6]. If you’ve had gallstones, your doctor will want to know.
Doctors also watch for pancreatitis, which means a sore and swollen pancreas, with GLP-1 drugs. Retatrutide studies left out people who had pancreatitis before. Phase 3 includes blood tests that may show pancreas trouble [12]. You can’t feel every blood-test change, so old results matter.
A small number in Phase 2 had a brief rise in a blood waste product at 12 mg [9]. That can mean the kidneys aren’t filtering as well. Another estimate of filtering dipped, then returned to or passed its starting point in the 8–12 mg groups. A kidney study now checks safety and possible help for kidney disease [13]. The short change isn’t a final answer. Your tests still matter.
Average pulse rose by a few beats each minute
In Phase 2, average pulse rose 2–5 beats per minute at lower amounts. It rose up to 6.7 beats per minute at 12 mg [14]. The third drug action can make the heart beat faster. That’s the likely cause, though one pulse reading can’t prove it.
Phase 2 reported no serious uneven heart rhythms. A Phase 3 study is still checking heart safety [19]. It follows people at high heart risk and counts major heart trouble, not only pulse changes.
The study sources page lists the papers behind each heart figure. If your pulse already concerns you, that’s a clear question to bring your doctor.
Fast retatrutide weight loss may cause short-term hair shedding
Some people with fast, large weight loss in Phase 2 reported short-term hair shedding. Doctors call it telogen effluvium [1]. The reports don’t prove retatrutide acted on the hair roots.
This kind of shedding can follow many forms of fast weight loss. Doctors have seen it after weight surgery, very low food intake, and other weight drugs. A sudden body change can stress hair roots and move more hairs into the shedding stage [1].
Studies haven’t found a hair or skin problem unique to retatrutide. In these reports, shedding most often eased after weight became steady. Your doctor can check other causes because a study report can’t diagnose your hair loss.
Retatrutide studies still need bone and kidney answers
TRIUMPH checks bone strength because fast, large weight loss can speed bone loss, mainly in older adults [12]. A bone-density scan shows how solid bones are. Final results aren’t ready. No one can fill that gap with a guess about your bones.
A small number in Phase 2 had more of a blood waste product at 12 mg [9]. That can mean weaker kidney filtering. Another kidney estimate dipped first, then rose above its starting point in the 8–12 mg groups. People differed, so the long safety study is checking more closely [9][19]. Your kidney numbers need their own review.
Phase 3 also watches hormone-making thyroid cells. Related GLP-1 weight drugs, which curb hunger, caused tumors in those cells in rodents. Phase 2 found no thyroid tumor warning in people taking retatrutide [12]. That helps, but it can’t settle your long-term risk.
Long-term retatrutide safety remains unknown
Safety facts beyond 48 weeks were limited in mid-2026. Longer TRIUMPH follow-up is still running. Added Phase 2 reports through early 2026 found no new serious problem beyond the first results [18]. That’s good news, but it isn’t years of use. A short study can’t fill the time gap.
Phase 3 is still checking bones, thyroid cells, gallstones, pancreas blood tests, kidneys, and major heart trouble [12][19]. Those findings will give a better view of long-term risk. For now, you won’t get an honest years-long answer.
Start with the known stomach and bowel problems. Then read how the drug acts, since the same actions may bring help and harm. Write down your main concern before the visit.